Kaituo Pharmaceutical-B (09939) released interim results, net loss of 75.782 million yuan, a year-on-year decrease of 8.99%

According to the Zhitong Finance App, Kaituo Pharmaceutical-B (09939) announced interim results up to 2026. Revenue increased from 6 million yuan in the same period last year to 52 million yuan for the six months ending June 30, 2026, with a net loss of 75.782 million yuan, a year-on-year decrease of 8.99%; loss per share was 0.15 yuan.

According to the announcement, the increase in revenue was mainly due to live e-commerce sales driving global sales of the new high-end cosmetics brand KOSHINÉ (KX-826, the main ingredient of which is one of the company's core products). The Group continues to explore different methods to further commercialize the company's cosmetics globally. The company plans to use cash flow from the cosmetics sales business to fund the development and commercialization of the company's core products KX-826 and GT20029, as well as other pipeline products. At the same time, the company will continue to strictly abide by the established guidelines for its listed business.

The decrease in net loss was mainly due to a reduction in the Group's R&D costs, partly offset by an increase in sales and marketing expenses, mainly due to increased marketing and promotion expenses.